Abstract：
OBJECTIVE: The relationship between chemotherapy response score (CRS), a widely used response predictor of neoadjuvant chemotherapy-interval debulking surgery (NAC-IDS), and multidrug resistance 1 (MDR1) and CA125 ELIMination rate constant K (KELIM), is undetermined. We evaluated CRS in advanced ovarian cancer patients undergoing NAC and looked for associations between CRS and MDR1 and CA125 KELIM. Our aim was to predict the therapeutic effect of NAC before interval debulking surgery (IDS) by examining its association with CRS.
METHODS: This retrospective cohort study included patients who underwent NAC-IDS (first-line treatment) at Kurume University Hospital, Japan, between 2004 and 2017. CRS association with MDR1 and CA125 KELIM was examined using Cox proportional hazard regression analyses. Survival curves used Kaplan-Meier method, and survival differences between groups used log-rank test.
RESULTS: Overall, 55 patients were classified into CRS1 (n=22), CRS2 (n=19), and CRS3 (n=14). The CRS3 group had a significantly better prognosis than the CRS1 or CRS2 group. CRS, age, and IDS status were clinical prognostic factors for ovarian cancer. MDR1 positivity for excision repair cross-complementing group 1, β-tubulin, and Y-box binding protein-1 occurred in 15, 17, and 11 patients, respectively, but these were not associated with CRS. CA125 KELIM was <0.5 (n=8), 0.5-1.0 (n=30), and ≥ 1.0 (n=17) but not associated with CRS.
CONCLUSIONS: CRS is reconfirmed as a treatment response predictor for NAC-IDS, but its association with drug resistance factors remains unconfirmed.
METHODS: This retrospective cohort study included patients who underwent NAC-IDS (first-line treatment) at Kurume University Hospital, Japan, between 2004 and 2017. CRS association with MDR1 and CA125 KELIM was examined using Cox proportional hazard regression analyses. Survival curves used Kaplan-Meier method, and survival differences between groups used log-rank test.
RESULTS: Overall, 55 patients were classified into CRS1 (n=22), CRS2 (n=19), and CRS3 (n=14). The CRS3 group had a significantly better prognosis than the CRS1 or CRS2 group. CRS, age, and IDS status were clinical prognostic factors for ovarian cancer. MDR1 positivity for excision repair cross-complementing group 1, β-tubulin, and Y-box binding protein-1 occurred in 15, 17, and 11 patients, respectively, but these were not associated with CRS. CA125 KELIM was <0.5 (n=8), 0.5-1.0 (n=30), and ≥ 1.0 (n=17) but not associated with CRS.
CONCLUSIONS: CRS is reconfirmed as a treatment response predictor for NAC-IDS, but its association with drug resistance factors remains unconfirmed.
摘要：
目的：化疗反应评分（CRS），一种广泛使用的新辅助化疗间隔减积手术(NAC-IDS)的反应预测因子，多药耐药1（MDR1）和CA125消除速率常数K（KELIM），是不确定的。我们评估了接受NAC的晚期卵巢癌患者的CRS，并寻找CRS与MDR1和CA125KELIM之间的关联。我们的目的是通过检查NAC与CRS的相关性来预测NAC在间隔减积手术（IDS）之前的治疗效果。
方法：这项回顾性队列研究包括在库鲁米大学医院接受NAC-IDS（一线治疗）的患者，Japan,2004年至2017年。使用Cox比例风险回归分析检查CRS与MDR1和CA125KELIM的相关性。生存曲线采用Kaplan-Meier法，组间生存差异采用对数秩检验。
结果：总体而言，55例患者分为CRS1（n=22），CRS2（n=19），和CRS3(n=14)。CRS3组的预后明显优于CRS1或CRS2组。CRS,年龄,和IDS状态是卵巢癌的临床预后因素。切除修复交叉互补组1的MDR1阳性，β-微管蛋白，Y盒结合蛋白-1发生在15、17和11例患者中，分别,但这些与CRS无关。CA125KELIM<0.5（n=8），0.5-1.0（n=30），≥1.0(n=17)，但与CRS无关。
结论：CRS被再次确认为NAC-IDS的治疗反应预测因子，但其与耐药因素的关联仍未得到证实。
方法：这项回顾性队列研究包括在库鲁米大学医院接受NAC-IDS（一线治疗）的患者，Japan,2004年至2017年。使用Cox比例风险回归分析检查CRS与MDR1和CA125KELIM的相关性。生存曲线采用Kaplan-Meier法，组间生存差异采用对数秩检验。
结果：总体而言，55例患者分为CRS1（n=22），CRS2（n=19），和CRS3(n=14)。CRS3组的预后明显优于CRS1或CRS2组。CRS,年龄,和IDS状态是卵巢癌的临床预后因素。切除修复交叉互补组1的MDR1阳性，β-微管蛋白，Y盒结合蛋白-1发生在15、17和11例患者中，分别,但这些与CRS无关。CA125KELIM<0.5（n=8），0.5-1.0（n=30），≥1.0(n=17)，但与CRS无关。
结论：CRS被再次确认为NAC-IDS的治疗反应预测因子，但其与耐药因素的关联仍未得到证实。
